A prognostication scoring system based on the expression levels of RNASEH2A-, CDK1-, and CD151-related genes could effectively predict the survival rate of RCC cancer patients (with a mean difference of four years in ccRCC). This evidence concerns the gene CD151 and nonpapillary renal cell carcinoma.